Work

Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions

Year: 2012

Type: review

Source: Pharmacology & Therapeutics

DOI: 10.1016/j.pharmthera.2012.06.005

Authors: Takumi Kiwamoto, Norihito Kawasaki, James C. Paulson, Bruce S. Bochner

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Scripps Research Institute

Language: English

Topic: Glycosylation and Glycoproteins Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Johns Hopkins University, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases

Awards: Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders, Glycobiology of Inflammatory Lung Diseases, Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders, G663223718, Regulation of Sialoside Expression in Leukocytes

OpenAlex ID: W1964729140

FWCI: 1.269

Cites: 109

Cited by: 190

Related to: 10